Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.
Innovations in The Management of Diabetes: Next generation treatments and market dynamics
Diabetes has become the fifth leading cause of death across developed markets, and cases of the disease are forecast to grow by 7.1% across the globe by 2013. The market for innovative diabetes treatments will be driven by this projected rise in prevalence, together with the substantial unmet need for drugs that can effectively halt or reverse disease progression.
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area.
Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies
Pricing and reimbursement strategies for innovative new drugs require significant evidence of beneficial clinical and economic outcomes using cost effectiveness and budget impact models.
The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses
The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry. Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs.
The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The Global Anti-infectives Market Outlook to 2013 provides comprehensive coverage of the anti-infectives market, incorporating the disease overview and detailed epidemiological analysis of the major indications.
Innovations and Pipelines for Respiratory Disorders: Niche markets, new products and future developments
‘Innovations and Pipelines for Respiratory Disorders’ is a report published by Business Insights that examines the future of the respiratory disorders market and explores the dynamics and drivers for current and emerging treatments.
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Neuropathic Pain - UCB's Vimpat set to compete with major players
The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach almost $3 billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast to take some $480m by 2017.
FarmavitaR+ Journal 
